← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biotherapeutics, Inc.
Blacksburg, VA
$12,557,201
Total funding
27
Grants
Funding over time
peak $3.2M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,557,201 · 27
By mechanism
R44$6,508,743 · 6
R43$5,860,125 · 20
R41$188,333 · 1
Investigators at Biotherapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A First-in-class Topical Immunoregulatory Therapeutic for Psoriasis$1,854,342
R44 · FY2025 · AR
Effects of Abscisic Acid on Insulin Sensitivity$933,303
R44 · FY2020 · DK
Validation of Immunometabolic NLRX1 Therapeutics for IBD$643,417
R44 · FY2021 · DK
Validation of Immunometabolic NLRX1 Therapeutics for IBD$634,825
R44 · FY2020 · DK
Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus$563,659
R44 · FY2022 · AI
Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus$563,659
R44 · FY2023 · AI
Effects of Abscisic Acid on Insulin Sensitivity$419,987
R44 · FY2021 · DK
Targeting the Immunometabolic Hub Nlrx1 as a Novel Therapeutic for Asthma$361,510
R43 · FY2021 · HL
Next-Gen Oral Therapeutics for Type 2 Diabetes$359,625
R43 · FY2025 · DK
Immunoregulatory Therapeutics for Ulcerative Colitis$356,068
R43 · FY2023 · DK
Development of Novel Immunoregulatory Therapeutics for Asthma$355,935
R43 · FY2024 · HL
The Next Wave of Asthma Therapeutics$347,608
R43 · FY2025 · HL
Novel Therapeutic for SLE$314,363
R44 · FY2025 · AI
Next-Gen Oral Therapeutics for Concomitant Clostridioides difficile Infection and IBD$314,363
R43 · FY2025 · AI
The First LANCL2-based therapeutic for influenza$300,000
R43 · FY2021 · AI
Comparative Efficacy of Therapeutics for Clostridioides difficile Infection$300,000
R43 · FY2024 · AI
Novel Immunoregulatory Therapeutics for Systemic Lupus Erythematosus$300,000
R43 · FY2021 · AI
Development of Antibiotic-Free Clostridium difficile Therapeutics$299,984
R43 · FY2019 · AI
BT-11: A First-in-class Oral Therapeutic for Inflammatory Bowel Disease$299,576
R44 · FY2018 · AI
Novel first-in-class Therapeutics for Rheumatoid Arthritis$295,924
R43 · FY2023 · AR